Maiwei Biological (688062.SH): The clinical trial application for 9MW1911 injection has been approved by the FDA.
Maiwei Biotechnology (688062.SH) announced that it has recently received the "Study May Proceed Notification" issued by the Food and Drug Administration (FDA) of the United States. The clinical trial application for 9MW1911 injection has officially been approved by the FDA.
Meiwei Bioscience (688062.SH) announced that the company has recently received the "Study May Proceed Notification" from the Food and Drug Administration (FDA) of the United States. The clinical trial application for 9MW1911 injection has officially obtained FDA approval.
9MW1911 is an innovative monoclonal antibody developed independently based on an efficient B lymphocyte selection platform. It belongs to the first class of therapeutic biologics and can bind with high affinity to the ST2 receptor, thereby blocking the IL33/ST2 signaling pathway.
Related Articles
HIPINE (02583) announces a year-on-year increase in net profit.
China New Holdings (08125): Li Ling Appointed as Chairman of the Company
ZHOU LIU FU (06168) stated that they are unaware of the reasons for the stock price movement, but the progress in their core business is going smoothly.
HIPINE (02583) announces a year-on-year increase in net profit.
China New Holdings (08125): Li Ling Appointed as Chairman of the Company
ZHOU LIU FU (06168) stated that they are unaware of the reasons for the stock price movement, but the progress in their core business is going smoothly.
RECOMMEND
